Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 23 Apr 2023
Despite Improvement Efforts, the "State of the Air" Report Highlights Issues.
Read Full NewsLong-acting injectable antipsychotics are linked to lower rehospitalization rates than oral antipsychotics in patients with bipolar I disorder, a study shows.
The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.
1.
AI innovation unlocks non-surgical way to detect brain cancer spread
2.
Infection tied to one-fourth of deaths with lower-risk myelodysplastic syndromes
3.
Survey: Record Numbers of US Adults Report Depression.
4.
La interacción GBP3-STING en el glioblastoma coordina la respuesta deficiente al temozolomide.
5.
Early Identification of Ovarian Cancer; Allergy Medicine for NSCLC? Unfavorable Development for Anti-TIGIT Medication?
1.
Advancing Cancer Care: Insights into Oncology Trials, Immunotherapy, and CAR-T Innovations
2.
Navigating the Complexity of Peritoneal Carcinomatosis: A Guide for Patients and Caregivers
3.
Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides
4.
The Science Behind Thrombolytic Drugs and Their Benefits
5.
Unveiling Tumor Immunity: Pan-Cancer Proteogenomics Characterization
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
3.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
5.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge